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Background: The mixed lineage leukemia (MLL) gene may induce hematopoiesis and 
leukemia. Partial tandem duplication of MLL (MLL-PTD) is associated with poor prog-
nosis in acute myeloid leukemia (AML); however, the significance of MLL-PTD in acute 
lymphoblastic leukemia (ALL) has not been thoroughly studied. We evaluated the in-
cidence, relationship with other cytogenetic abnormalities, and the prognostic role of 
MLL-PTD in ALL.
Methods: We reviewed medical records from pediatric patients diagnosed with ALL in 
Severance Hospital, Yonsei University Health System, South Korea from 2002 to 2008. 
MLL-PTD was detected by nested reverse transcriptase polymerase chain reaction.
Results: In ALL patients, 50.0% (42/84) were positive for MLL-PTD. There was no sig-
nificant difference in the 10-year overall survival (10Y OS) and event-free survival (EFS) 
between MLL-PTD-positive (+) and MLL-PTD-negative (–) groups (69.4% vs. 76.2%, 
P=0.609, and 62.6% vs. 66.7%, P=0.818, respectively). The combination of high level 
of lactate dehydrogenase (＞1,100 IU/L) and MLL-PTD(+) [MLL-PTD(+)/High LDH] was 
a statistically significant negative prognostic factor for 10Y OS and EFS (P=0.0226 and 
P=0.0230, respectively). In multivariate analysis, National Cancer Institute risk strat-
ification and very high risk features were independent significant prognostic factors but 
MLL-PTD (+)/High LDH was not.
Conclusion: MLL-PTD was observed frequently in pediatric ALL patients. MLL-PTD was 
not an independent prognostic factor. MLL-PTD (+)/High LDH should be evaluated fur-
ther for its prognostic potential in ALL.
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Introduction
Chromosomal rearrangements in the hematopoietic sys-
tem are regarded as key events in development and leuke-
mogenesis [1,2]. The mixed lineage leukemia (MLL) gene 
is located on chromosome 11q23 and has been extensively 
investigated. MLL is a human homolog of Drosophila mela-
nogaster trithorax. In Drosophila, the trithorax group and 
the polycomb group appear to play opposing roles in the 
regulation of gene expression [1]. The 90-kb MLL gene enc-
odes a 430-kDa protein comprising 3969 amino acid resi-
dues [2] that has methylase and acetylase activities. The 
MLL gene forms various rearrangements with over 50 part-
ner genes, and the most common MLL fusion partners are 
AF4, AF9, ENL, AF6, ELL, and AF10 [3]. MLL is associated 
with leukemia transformation, and the MLL gene rearrange-
ment is associated with poor prognosis of both acute lym-
phoblastic leukemia (ALL) and acute myeloid leukemia 
(AML).
MLL partial tandem duplication (MLL-PTD) is an MLL 
gene rearrangement that is observed in 5-10% of adults with 
AML [3]; however, the incidence is quite varied depending 
on karyotype. Although the incidence of MLL-PTD is about 
11% in unselected AML, it is 5.7-21% for karyotypically nor-
mal AML and even higher, 13.6-54%, in AML with trisomy 
11 [3]. Most of these studies were conducted in the adult 
population, and it is possible that the incidence of MLL-PTD 
is higher in pediatric AML. For example, Ross et al. [4] re-
ported that 27.7% of karyotypically normal pediatric AML 
subjects had MLL-PTD.
There are fewer studies on the incidence of MLL-PTD in 
ALL patients. MLL is an essential factor in the development 
of hematopoietic cells [5]. Since MLL translocations are 
thought to be involved in leukemogenesis, certain trans-
locations might result in ALL. In one study, Pallisgaard et 
al. found MLL-PTD in 12.9% (8/62) of ALL patients [6], but 
more data on MLL-PTD in ALL are needed.
In this study, we investigated the frequency, relationship 
with other cytogenetic abnormalities, and prognostic im-
plications of MLL-PTD in ALL. We also studied MLL-PTD 
in the pediatric population, the field where there is the least 
amount of data. This study was conducted in an Asian pop-
ulation and could be used to elucidate ethnic differences 
in the incidence of MLL-PTD.
Methods
1) Patients
Between March 2002 and May 2008, 149 pediatric patients 
were diagnosed with ALL at Severance Hospital in Yonsei 
University Health System. During this period, 106 patients 
with ALL were treated in the institution, but 22 patients with 
ALL were excluded from the study because they were treated 
for relapse during the study period, and their MLL-PTD sta-
tus, including their initial diagnosis and treatment before 
March 2002, was unclear. As a result, 84 patients diagnosed 
with ALL were used in this study. All cases were morphologi-
cally diagnosed according to French-American-British (FAB) 
classification. Bone marrow samples from patients were 
drawn and analyzed in the laboratory department of the 
institution. The samples were subject to immunophenotyp-
ing and molecular subtyping. The MLL-PTD test (described 
below) was performed at the time of diagnosis for patients 
diagnosed with ALL from 2002 to 2008. The positive 
MLL-PTD status was verified by correlating with patient med-
ical records.
2) Treatment Strategy
ALL patients were classified as standard risk (ALL-SR) or 
high risk (ALL-HR) according to age and white blood cell 
(WBC) count using the National Cancer Institute (NCI) risk 
stratification. Patients who were initially assigned to the 
ALL-SR group and were later found to have adverse trans-
locations, including t(9;22), various 11q23 translocations, 
and MLL-PTD, were treated with the ALL-HR protocol. 
ALL-SR and -HR protocols were based on the Children’s 
Cancer Group (CCG) 1991 and CCG 1961 protocols, 
respectively. Hematopoietic stem cell transplant was con-
sidered for patients with the following characteristics: WBC 
count ＞100,000/L, presence of t(9;22) or t(4;11) trans-
location, infantile leukemia (age younger than 1 year at di-
agnosis), induction failure, or patients in second or more 
remission after relapse or with secondary leukemia.
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3) Detection of MLL-PTD using Reverse Transcriptase 
Polymerase Chain Reaction (RT-PCR)
Total cellular RNA was isolated from bone marrow samples 
at diagnosis using Tri Reagent (BD, Molecular Research 
Center, Inc., 5645 Montgomery Road, Cincinnati, OH, USA). 
RNA was reverse transcribed to cDNA using a cDNA Synthesis 
Kit (Roche, USA). Nested RT-PCR was performed using Taq 
polymerase (Poschem, Korea) for 30 cycles with the following 
primers: 3.1c (5´ -AGGAGAGAGTTTACCTGCTC-3´ ) from 
exon 3, 5.3 (5´ -GGAAGTCAAGCAAGCAGGTC-3´ ) from 
exon 5, 6.1 (5´ -GTCCAGAGCAGAGCAAACAG-3´ ) from 
exon 6, and 3.2c (5´ -ACACAGATG-GATCTGAGAGG-3´ ) 
from exon 3 based on the literature [7]. PCR products were 
analyzed by electrophoresis on 1.5% agarose gels. We in-
cluded a sample known to contain MLL-PTD as a positive 
control and distilled water as a negative control.
4) Comparison of prognosis
In ALL, patients were grouped into ALL-SR and ALL-HR 
groups according to NCI risk stratification. Parameters 
known to affect prognosis for ALL were recorded and 
analyzed. Early death was defined as death within 6 
months from diagnosis. MLL-PTD (+) and MLL-PTD (–) 
groups were defined according to the status of MLL-PTD 
detection. The patient population was divided into two 
groups based on lactate dehydrogenase (LDH) level. The 
high-LDH group was defined by an LDH level higher than 
1,100 IU/dL. The low-LDH group was defined by an LDH 
level of 1,100 IU/dL or lower. The cut-off point of LDH 
classification was determined using receiver operating char-
acteristic analysis for death event. We combined MLL-PTD 
status and LDH level in the survival analysis as follows: 
MLL-PTD (+)/High LDH compared to all others [MLL-PTD 
(+)/Low LDH, MLL-PTD (–)/High LDH, and MLL-PTD 
(–)/Low LDH]. Very high risk factor (VHR factor), which 
was considered as acceptable transplant indication at first 
complete remission, was defined as the presence of t(9;22) 
or t(4;11) translocation, infantile leukemia (age younger 
than 1 year at diagnosis), and induction failure.
5) Statistical Analysis
The chi-square test was used to evaluate the difference 
between categorical variables in patient characteristics. For 
survival analysis, the start point was diagnosis date and the 
end point was the occurrence of an adverse event (relapse 
or death). Event-free survival (EFS) was defined as time 
from diagnosis to the occurrence of the first adverse event, 
including relapse, progression, or death. Overall survival 
(OS) was defined as time from diagnosis to the death in-
curred by any cause. The Kaplan-Meier method was used 
for survival analysis, and the difference in OS between 
groups was evaluated by the log-rank test. Multivariate 
analysis was performed using a Cox proportional hazards 
regression model. Statistical significance was considered 
when the P-value was less than 0.05.
Results
1) MLL-PTD in ALL
MLL-PTD was detected in 50.0% (42/84) of ALL patients 
(Table 1). The mean age at diagnosis of the MLL-PTD (+) 
group was 5.63±3.79 years, and was not statistically differ-
ent from that of the MLL-PTD (–) group (6.26±4.28 years, 
P=0.480). There was no difference in initial WBC count be-
tween the MLL-PTD (+) group and the MLL-PTD (–) group 
(56,100±20,200 vs. 47,500±12,500, respectively, P=0.717). 
There was no statistical difference between the two groups 
in the proportion of high-risk patients, hemoglobin levels, 
platelet counts, or FAB subtypes (Table 1).
The LDH level was significantly higher in the MLL-PTD 
(–) group than in the MLL-PTD (+) group (3,380±650 vs. 
1,230±210, P=0.003). MLL-PTD (+) was significantly corre-
lated with low LDH defined by an LDH level less than 
1,100 IU/dL (P=0.011).
There was no difference between the two groups in the 
frequency of minor BCR-ABL and TEL-AML1 rearrange-
ments, whereas the frequency of E2A-PBX rearrangement 
was greater in the MLL-PTD (–) group than in the MLL-PTD 
(+) group (P=0.054). In the MLL-PTD (+) group, 31/40 
(77.5%) patients were cytogenetically normal. In cytoge-
netically normal patients, 31/62 (50%) had MLL-PTD.
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Table 1. Clinical characteristics of acute lymphoblastic leukemia patients
MLL-PTD(+) MLL-PTD(-) P-value
No. of cases
Age at diagnosis (mean, years)
Sex (male : female)
WBC (mean, 109/L)
Hemoglobin (mean, g/dL)
Platelets (mean, 109/L)
LDH (mean, IU/L)
NCI risk group
  Standard
  High
FAB subtype
  L1
  L2
  L3
Gene rearrangement
  BCR-ABL (n=78)
  TEL-AML1 (n=80)
  E2A-PBX (n=71)
  MLL-AF4 (n=40)
CALLA-positive
CR rate
42
5.63±3.79
22:20
56,100±20,200
7.42±2.71
100,800±16,200
1230±210
 
27
15
 
33
 8
 0
 
 1
10
 0
 0
31
2 (95.3%)
42
6.26±4.28
20:22
47,500±12,500
8.05±2.93
104,600±18,400
3,380±650
 
27
15
 
36
 7
 2
 
 1
 8
 4
 0
30
2 (95.3%)
 
0.480
0.663
0.717
0.319
0.879
0.003
 
1.000
 
 
0.365
 
 
 
1.000
0.591
0.054
 
0.949
1.000
MLL, mixed lineage leukemia gene; CALLA, common ALL antigen; CI, confidence interval; CR, complete remission; FAB, 
French-American-British; LDH, lactate dehydrogenase; NCI, National Cancer Institute; WBC, white blood cell.
Fig. 1. Probability of Survival in Acute Lymphoblastic Leukemia (ALL) Patients according to the Mixed Lineage Leukemia Gene –
Partial Tandem Duplication (MLL-PTD) status. (A) Overall Survival. (B) Event-Free Survival.
In this study population, there were 4 infantile leukemia 
patients, and 3/4 (75%) of them had MLL-PTD. However, 
the MLL-AF4 translocation was not observed in these 
patients. The complete remission rate was not significantly 
different between the groups (P=0.345).
2) Outcome in ALL
The median follow-up duration for leukemia patients 
who survived was 8.8 years (range, 0.9-12.4 years). The 
10-year overall survival (10Y OS) rate was 72.4±4.9%. The 
10-year event-free survival (10Y EFS) rate was 64.7±5.3%. 
The 10Y OS of the ALL-SR group was significantly higher 
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Fig. 2. Probability of Survival in Acute Lymphoblastic Leukemia (ALL) Patients according to Mixed Lineage Leukemia Gene – Partial
Tandem Duplication (MLL-PTD) and Lactate Dehydrogenase (LDH) Status. (A) Overall Survival. (B) Event-Free Survival.
than that of the ALL-HR group (84.4% vs. 51.9% P
＜0.0001). The 10Y EFS of the ALL-SR group was sig-
nificantly higher than that of the ALL-HR group (79.6% vs. 
38.0% P＜0.0001).
3) OS and MLL-PTD (Fig. 1A)
The 10Y OS rate was not significantly different between 
the MLL-PTD (+) and (–) groups (69.4% vs. 76.2% re-
spectively, P=0.609). The 10Y EFS rate was 64.7%±5.3%. 
In both the ALL-HR and ALL-SR groups, the MLL-PTD (+) 
group had a similar but slightly lower survival rate than the 
MLL-PTD (–) group (ALL-SR, 79.3±8.4% vs. 88.9±6.0%, 
P=0.441; ALL-HR, 50.3±13.4% vs. 53.3±12.9%, P=0.904).
4) EFS and MLL-PTD (Fig. 1B)
The 10Y EFS rate was not significantly different between 
the MLL-PTD (+) and (–) groups (62.6% vs. 66.7% re-
spectively, P=0.818). 
In both the ALL-HR and ALL-SR groups, the MLL-PTD (+) 
group had a similar but slightly lower survival rate than the 
MLL-PTD (–) group (ALL-SR, 76.9±8.3% vs. 81.5±7.5%, 
P=0.763; ALL-HR, 35.9±12.8% vs. 40.0±12.6%, P=0.900) 
(Fig. 1D, 1E).
5) Treatment Strategy in the MLL-PTD (+) Group
Most of the patients (39/42, 92.9%) in the MLL-PTD (+) 
group were treated with the HR risk protocol regardless of 
NCI risk stratification; the other 3 patients in the MLL-PTD 
(+) group were treated with the SR risk protocol. There was 
no survival difference between the 3 patients treated with 
the SR protocol and those treated with the HR protocol 
(66.7% vs. 71.8%, P=0.972). In the MLL-PTD (+) group, 
hematopoietic stem cell transplantation was performed in 
11 patients: 3 of them received the transplantation because 
of relapse, 3 for an initial WBC count ＞100,000/L, 2 for 
infantile leukemia, 1 for uncontrolled initial central nervous 
leukemia, and 2 for induction failure. There was no differ-
ence in survival among initial SR protocol approach vs. HR 
protocol approach vs. transplantation approach (P=0.445).
6) Outcome Analysis According to LDH and MLL-PTD Status
The patient population was divided into two groups based 
on LDH level. The 10Y OS and 10Y EFS of the high-LDH 
group (LDH level ＞1,100 IU/L) was significantly lower than 
that of the low-LDH group (59.4% vs. 81.6%, P=0.0226; 
50.0% vs. 74.1%, P=0.0230, respectively) (Fig. 2A). In the 
ALL-SR group, the 10Y OS rate of the high-LDH group was 
significantly lower than that of the low-LDH group (70.6% 
vs. 90.9%, P=0.0369). The 10Y EFS rate according to LDH 
group showed a trend of higher survival in the low-LDH 
group (86.1% vs. 64.7%, P=0.064). In the HR group, the 
10Y OS of the high-LDH group was not significantly different 
from that of the low-LDH group (46.7% vs. 57.1%, P=0.467; 
33.3% vs. 42.9%, P=0.634, respectively).
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Table 2. Multivariate analysis of prognostic factors for survival in acute lymphoblastic leukemia patients
Factor
Overall survival Event-free survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
NCI high risk
VHR
High LDH
MLL-PTD
2.45
4.90
2.18
1.22
0.94-6.42
1.78-13.50
0.81-5.86
0.45-3.32
0.680
0.002a)
0.122
0.690
3.06
2.65
1.79
1.13
1.33-7.03
1.05-6.69
0.78-4.12
0.49-2.62
0.008a)
0.040a)
0.170
0.768
CI, confidence interval; LDH, lactate dehydrogenase; MLL-PTD, mixed lineage leukemia-partial tandem duplication; NCI, National 
Cancer Institute; VHR, very high risk; WBC, white blood cell.
a)Statistically significant (P＜0.05).
Combining MLL-PTD status and LDH level in the survival 
analysis, the group with both MLL-PTD (+) and high LDH 
[MLL-PTD(+)/High LDH group] showed the lowest 10Y OS 
and EFS rates (37.5%, P=0.040 and 37.5%, P=0.094, re-
spectively) (Fig. 2).
7) Multivariate Analysis (Table 2)
In the multivariate analysis for OS, VHR factor was an 
independent risk factor (Hazard Ratio [HR]=4.90, P=0.002). 
NCI high risk showed an inferior trend (HR 2.45, P=0.068), 
but high LDH and MLL-PTD status were not independent 
risk factors (HR 2.18, P=0.122 and HR 1.22 P=0.690, re-
spectively). For EFS, VHR factor and NCI high-risk strat-
ification were independent risk factors (HR 2.65, P=0.040, 
and HR 3.06, P=0.008, respectively) but high LDH and 
MLL-PTD status were not (HR=1.79, P=0.170 and HR=1.13, 
P=0.768).
We examined the combined factor as MLL-PTD (+)/High 
LDH in the analysis. VHR factor and NCI high risk were 
independent predictors for OS and EFS, but MLL-PTD 
(+)/High LDH was not an independent risk factor (HR 1.77, 
P=0.296 for OS, HR 1.28, P=0.633 for EFS) (Table 2).
Discussion
In this study, MLL-PTD was frequently observed in ALL 
and AML, which are well known leukemias associated with 
MLL-PTD. We evaluated the prognostic significance of 
MLL-PTD, but it was not an independent risk factor in ALL 
for survival in univariate analysis. However, MLL-PTD was 
significantly associated with LDH level in ALL and influ-
enced the prognosis of the ALL-SR group. Overall, 
MLL-PTD (+)/High LDH group was an independent risk fac-
tor for survival in ALL.
In this study, the prevalence of MLL-PTD was high com-
pared with other reports [3]. This difference may reflect the 
detection method used for MLL-PTD. When using a nested 
RT-PCR, MLL-PTD can be detected in 17-100% of whole 
blood and bone marrow samples from normal healthy do-
nors [8,9]. According to the authors of these studies, a mu-
tation such as MLL-PTD that is not lethal might be observed 
in healthy individuals throughout life. MLL-PTD is even de-
tected in cord blood samples of newborns, suggesting it is 
present from the early stages of development [10]. 
Therefore, the MLL gene is believed to play a role in nor-
mal hematopoiesis and leukemogenesis, although it is not 
clear whether the MLL gene acts as an oncogene, a sup-
pressor gene, or a dominant negative gene [2]. The high 
positivity rate of MLL-PTD in healthy donors is not much 
different from that of other gene rearrangements found in 
leukemias: t(9;22), BCR-ABL, t(8;21), and AML1-ETO. Many 
other translocations are detectable in healthy donors and 
are involved in non-neoplastic hematopoiesis and leukemo-
genesis [11].
However, there is a major difference in the frequency of 
MLL-PTD transcripts between leukemia patients and healthy 
donors. When conventional nested PCR was used for de-
tection, MLL-PTD could be detected in healthy individuals 
in the nested cycle only, whereas in AML patients, the am-
plification was evident during the primary PCR [3]. To re-
duce false positives during detection of MLL-PTD, many re-
searchers use simple, single-round RT-PCR instead of nest-
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ed RT-PCR [12-14]. The quantitation of MLL-PTD and its 
clinical application to treat leukemia are currently under in-
vestigation [15].
Although nested RT-PCR has certain limitations, it is a 
standard method for the detection of MLL-PTD, and many 
researchers have reported valuable findings using this ap-
proach [16-18]. When results from other studies using nest-
ed PCR were compared with our findings, the detection 
rate of MLL-PTD in our study was higher. In previous stud-
ies, MLL-PTD was detected in 5-11% of the subjects, where-
as we detected MLL-PTD in over 40% of our patients with 
ALL. One possible reason for this discrepancy is the differ-
ence in age of the study population. In the adult pop-
ulation, 5-10% of MLL-PTD positivity is considered a normal 
range [3], but the positivity in pediatric populations tends 
to be somewhat higher and has been reported to be 13.3% 
(21/158), 27.7% (13/47), and 40% (2/5) in different studies 
[4,13,18]. Geographic or ethnic differences could also affect 
the positivity rate. Recent studies of Asian populations, in-
cluding those in Japan and Taiwan, reported a higher fre-
quency of MLL-PTD than in other studies elsewhere [13,18]. 
To validate these hypotheses, further studies on the pedia-
tric population with varying ethnicities are needed.
To our knowledge, this is the first large study of 
MLL-PTD in ALL. Using nested RT-PCR, we detected 
MLL-PTD in a very high percentage (47.6%) of pediatric 
ALL patients. Theoretically, since the MLL gene acts in hem-
atopoiesis and is thought to be associated with leukemo-
genesis, the mutation of this gene could lead to various 
types of leukemia. Quentmeier et al. screened a panel of 
cell lines (66 AML and 73 ALL cell lines) for the MLL-PTD 
mutation [19]. They proposed that the MLL breakpoint clus-
ter region (BCR) of the MLL gene might be involved in 
MLL-PTD in addition to translocations, and therefore 
MLL-PTD might be common in ALL and AML. However, of 
the 139 cell lines tested, only four carried the MLL-PTD mu-
tation, and all of these were AML-derived. In contrast, 
Pallisgaard et al. reported that 12.9% (8/62) of pediatric ALL 
patients had MLL-PTD [6], and this is one of the few studies 
to report MLL-PTD in ALL other than our study.
MLL-PTD in AML is accepted as a poor prognostic factor, 
but this remains controversial [3,20]. Schnittger et al. re-
ported that the median survival and relapse free interval of 
the MLL-PTD (+) group were significantly worse than those 
of an age-matched karyotypically normal control group [14]. 
Yu et al. studied MLL-PTD in normal karyotype adult AML 
subjects and showed that 7 out of 34 patients had a median 
survival of 2.7 months, compared to a 6.8-month median 
survival for all other patients [21]. However, several other 
reports do not support the notion that MLL-PTD is an in-
dependent risk factor for AML. Dohner et al. studied adult 
AML patients with normal cytogenetics and showed that the 
OS rate between MLL-PTD-positive and -negative groups 
was not statistically different (P=0.427), but the duration of 
remission of the MLL-PTD-positive group was significantly 
lower than that of the MLL-PTD-negative group (P=0.02) 
[12]. However, Shih et al. reported no difference in OS rate 
or remission duration between MLL-PTD-positive AML pa-
tients and patients with other 11q23 rearrangements [22]. 
Moreover, Whitman et al., in a Cancer and Leukemia 
Group B (CALGB) study, and Steudel et al. concluded that 
MLL-PTD was not an independent prognostic factor for OS 
or EFS [16,17]. Considering these controversial results, the 
prognostic impact of MLL-PTD might be weaker than pre-
viously thought.
Prognosis of MLL-PTD (+) ALL patients has not pre-
viously been reported. In our study, MLL-PTD was not an 
independent prognostic factor for ALL in the SR or the HR 
group. LDH is a well-known prognostic factor in leukemia 
[23]. The LDH level was associated with the prognosis of 
ALL, mainly due to its effect on ALL-SR. The cut-off point 
was 1,100 IU/L in this study, and this was consistent with 
other ALL studies [24,25]. Pui et al. studied the prognostic 
implication of LDH in 293 standard risk ALL patients, and 
the cut-off value was 1,000 IU/dL [23]. ALL-SR is defined 
by age and WBC count. ALL-SR is homogenous, and LDH 
might have a clear impact on the survival rate in this group 
of patients. In contrast, the ALL-HR group is quite heteroge-
neous and includes several patient characteristics with 
strong adverse prognostic values such as BCR/ABL and 
MLL/AF4. Therefore, the prognosis of ALL-HR is not influ-
enced by weak individual prognostic factors such as LDH. 
Initially, MLL-PTD was associated with a lower LDH 
level. However, few patients showed high LDH levels com-
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bined with positive MLL-PTD (N=9), and it was significantly 
associated with adverse outcomes (Fig. 2). MLL-PTD and 
high LDH were not independent risk factors for OS or EFS 
in multivariate analysis. NCI high risk and VHR factor were 
strong risk factors for survival. One of the reasons is the 
association between MLL-PTD (+)/high LDH and VHR 
factor. In the MLL-PTD (+)/High LDH group, 33.3% (3/9) 
of patients had VHR factor, which was significantly higher 
than the VHR factor frequency of other patients (9.3%, 
7/75, P=0.036). In the ALL-SR patients without VHR factors, 
MLL-PTD (+)/High LDH showed inferior OS and EFS 
(50.0% vs. 91.0%, P=0.010 and 50.0% vs. 85.1%, P=0.083, 
respectively). Therefore, MLL-PTD (+)/High LDH would be 
another prognostic factor next to the NCI risk stratification 
and VHR features, especially in the cytogenetically normal 
ALL group. The implication of this combined factor should 
be evaluated later with much more cytogenetically normal 
ALL patients.
Our study has some unique features. To our knowledge, 
this is the first large study of MLL-PTD in ALL patients. The 
patients were followed up for a long period of time (over 
9 years). This study provides information about MLL-PTD 
in the pediatric population, which has not been extensively 
studied. Moreover, the study involved Asian patients and 
may reveal characteristics specific to ethnicity. This study 
also has some limitations: MLL-PTD was detected by nested 
RT-PCR, not by single-round RT-PCR. MLL-PTD-positive pa-
tients were treated with high-risk ALL chemotherapy proto-
cols, and so this high intensity might have influenced the 
survival results in the MLL-PTD-positive group. High-in-
tensity chemotherapy might overcome the potential adverse 
prognostic implication of MLL-PTD in ALL.
In conclusion, this is the first report on the prevalence 
of MLL-PTD in ALL patients. As an independent factor, 
MLL-PTD did not show prognostic power for survival. The 
MLL-PTD-positive and high LDH group should be evaluated 
further for prognostic potential.
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